Compare · AGEN vs BTX
AGEN vs BTX
Side-by-side comparison of Agenus Inc. (AGEN) and BlackRock Technology and Private Equity Term Trust (BTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- BTX is the larger of the two at $1.82B, about 6.0x AGEN ($304.5M).
- AGEN has been more active in the news (8 items in the past 4 weeks vs 1 for BTX).
- AGEN has more recent analyst coverage (13 ratings vs 2 for BTX).
- Company
- Agenus Inc.
- BlackRock Technology and Private Equity Term Trust
- Price
- -
- -
- Market cap
- $304.5M
- $1.82B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- 2021
- News (4w)
- 8
- 1
- Recent ratings
- 13
- 2
Agenus Inc.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFÃ TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
BlackRock Technology and Private Equity Term Trust
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company is based in Brooklyn, New York.
Latest AGEN
- SEC Form SCHEDULE 13G filed by Agenus Inc.
- Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026
- SEC Form 10-Q filed by Agenus Inc.
- Agenus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
- Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat
- Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
- Agenus to Provide Third Quarter 2026 Financial Report and Development Update
- Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Latest BTX
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
- Amendment: SEC Form N-CEN/A filed by BlackRock Technology and Private Equity Term Trust
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
- SEC Form 3 filed by new insider Mahoney Francis C.
- Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds
- SEC Form N-CSRS filed by BlackRock Technology and Private Equity Term Trust
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
- SEC Form N-PX filed by BlackRock Technology and Private Equity Term Trust
- SEC Form 3 filed by new insider Park Charles
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions